Clinical Observation of on-Demand Intraperitoneal Injection of Endostar on Advanced Gastric Cancers with Malignant Ascites

WANG Zhiming,LIU Tianshu,LI Qian,FENG Yi,ZHUANG Rongyuan,SONG Yan,CHEN Yong,ZHOU Yuhong,JIN Wen
DOI: https://doi.org/10.3969/j.issn.1008-6358.2011.04.016
2011-01-01
Abstract:Objective:To observe the clinical efficacy of on-demand injection of endostar(recombinant human endostatin,a new generation of anti-angiogenesis agent) on ascites of advanced gastric cancers,and evaluate the safety and tolerability of intraperitoneal application of the endostar.Methods: Oral fluoropyrimidine were applied for 5 patients with advanced gastric cancer for maintenance therapy.During the procedure of maintenance therapy,the 5 patients emerged noticeable symptoms of ascites,but with stable tumor masses.Following a maximum release of peritoneal cavity fluid,endostar 30mg was injected into peritoneal cavity.Then palliative withdrawal of fluids and on-demand intraperitoneal injections of endostar were given according to the symptoms of abdominal distension,and to investigate its clinical efficacy,quality of life,loss of ascites protein,as well as toxicity.Results: Five cases of patients could be evaluated by its efficacy and safety.All patients were found to decrease amounts of peritoneal cavity fluid,reduce loss of ascites protein and improve their quality of life but without drug-related toxicity.Conclusions: On-demand intraperitoneal injection of endostatin can better control the malignant ascites,reduce the clinical symptoms,improve the patients quality of life in the patients with advanced gastric cancers.Clinical safety is better.
What problem does this paper attempt to address?